Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Факторы, определяющие эффективность эрадикационной терапии Helicobacter рylori-ассоциированных заболеваний
Факторы, определяющие эффективность эрадикационной терапии Helicobacter рylori-ассоциированных заболеваний
О.А.Саблин, Н.В.Михайлов, М.В.Юрин, Т.А.Ильчишина, А.С.Кондрашин, М.Г.Кобиашвили, И.А.Михайлова, А.В.Сварваль, А.Б.Жебрун. Факторы, определяющие эффективность эрадикационной терапии Helicobacter рylori-ассоциированных заболеваний. Consilium Medicum. Гастроэнтерология (Прил.). 2011; 2: 8-12.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Богун Л.В. Инфекция Helicobacter pylori: вопросы резистентности и современные подходы к эрадикационной терапии. Новости фармации и медицины. 2011; 8: 362.
2. Дехнич Н.Н., Костякова Е.А., Пунин А.П. и др. Антибиотикорезистентность H. pylori: результаты микробиологического регионального исследования. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2011; 2: 37–42.
3. Жебрун А.Б., Александрова В.А., Гончарова Л.Б., Ткаченко Е.И. Диагностика, профилактика и лечение заболеваний, ассоциированных с Helicobacter pylori-инфекцией. СПб, 2002.
4. Кишкун А.А. Современные методы диагностики и оценки лечения инфекции Helicobacter pylori. Лабораторная медицина. 2000; 3: 37–44.
5. Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». Клин. микробиол. антимикроб. химиотерапия. 2004; 4: 306–57.
6. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич, 1998.
7. Abdullahi M, Annibale B, Capoccia D et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450–4.
8. Abuzarova ER, Abdulkhakov RA, Chernov VM et al. Prevalence of A2143G, A2142G and T2717C mutations of H.pylori-23S rRNA in Kazan (Russia). Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P 07.11.
9. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163–71.
10. Baryshnikova NV, Uspenskiy YP, Suvorova MA, Suvorov AN. Helicobacter pylori resistance to Claritromycin in duodenal ulcer patients in Saint-Petersburg. Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P 07.19.
11. Broutet N, Tchamgoué S, Pereira E et al. Risk factors for failure of Helicobacter pylori therapy – results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99–109.
12. Byun Y, Jo Y, Kim S et al. Clinical factors that predicts successful eradication of Helicobacter pylori. Korean J Gastroenterol 2006; 48: 172–9.
13. Camargo M, Piazuelo M, Mera R et al. Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. Acta Gastroenterol Latinoam 2007; 37: 238–45.
14. Cars O, Molstad S, Melander Z. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–3.
15. Cho D, Park S, Kee W et al. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterol 2010; 55: 368–75.
16. Connolly L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007; 4: 120.
17. De Francesco V, Zullo A, Margiotta M et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407–14.
18. Duck W, Sobel J, Pruckler J et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 6: 1088–94.
19. Georgopoulos S, Ladas S, Karatapanis S et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig Dis Sci 2000; 45: 63–7.
20. Graham D, Lew G, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterol 1992; 102: 493–6.
21. Graham D, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321–31.
22. Gisbert J, Hermida C, Pajares J. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in nonulcer dyspepsia? Hepatogastroenterol 2001; 48: 1383–8.
23. Gumurdulu Y, Serin E, Ozer B et al. Low eradication rate of Helicobacter pylori with triple 7–14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668–71.
24. Katelaris PH. Helicobacter pylori: why are eradication results so variable? J Gastroenterol Hepatol 2004; 19: 606–9.
25. Koivisto T, Rautelin H, Voutilainen M et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 2005; 9: 1009–17.
26. Lazebnik LB, Bordin DS, Belousova NL et al. Frequency of site-specific mutations in the 23S rRNA gene of Helicobacter pylori in Moscow. Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P. 07.21.
27. Lee J, Shin J, Roe I et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005; 4: 1600–3.
28. Mamori S, Higashida A, Kawara F et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol 2010; 16: 4176–9.
29. McMahon B, Hennessy T, Bensler J et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections 2003; 6: 463–9.
30. Mеgraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280–322.
31. Moder K, Layer F, König W, König B. Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing. J Med Microbiol 2007; 56: 1370–6.
32. Noguchi N, Rimbara E, Kato A. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J Med Microbiol 2007; 9: 1174–80.
33. Silva F, Zaterka S, Eisig J et al. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo 2001; 56: 11–6.
34. Stark R, Gerwig G, Pitman R et al. Letters in applied microbiology. 1999; 2: 121–6.
35. Sugimoto M, Furuta T, Kodaira C et al. The Degree and Duration of Acid Suppression During Treatment Is Related to Helicobacter pylori Eradication. DDW 2008.
36. Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217–24.
37. Yakoob J, Abid S, Abbas Z, Jafri S. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010; 67: 197–201.
2. Дехнич Н.Н., Костякова Е.А., Пунин А.П. и др. Антибиотикорезистентность H. pylori: результаты микробиологического регионального исследования. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2011; 2: 37–42.
3. Жебрун А.Б., Александрова В.А., Гончарова Л.Б., Ткаченко Е.И. Диагностика, профилактика и лечение заболеваний, ассоциированных с Helicobacter pylori-инфекцией. СПб, 2002.
4. Кишкун А.А. Современные методы диагностики и оценки лечения инфекции Helicobacter pylori. Лабораторная медицина. 2000; 3: 37–44.
5. Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». Клин. микробиол. антимикроб. химиотерапия. 2004; 4: 306–57.
6. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич, 1998.
7. Abdullahi M, Annibale B, Capoccia D et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450–4.
8. Abuzarova ER, Abdulkhakov RA, Chernov VM et al. Prevalence of A2143G, A2142G and T2717C mutations of H.pylori-23S rRNA in Kazan (Russia). Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P 07.11.
9. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163–71.
10. Baryshnikova NV, Uspenskiy YP, Suvorova MA, Suvorov AN. Helicobacter pylori resistance to Claritromycin in duodenal ulcer patients in Saint-Petersburg. Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P 07.19.
11. Broutet N, Tchamgoué S, Pereira E et al. Risk factors for failure of Helicobacter pylori therapy – results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99–109.
12. Byun Y, Jo Y, Kim S et al. Clinical factors that predicts successful eradication of Helicobacter pylori. Korean J Gastroenterol 2006; 48: 172–9.
13. Camargo M, Piazuelo M, Mera R et al. Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. Acta Gastroenterol Latinoam 2007; 37: 238–45.
14. Cars O, Molstad S, Melander Z. Variation in antibiotic use in the European Union. Lancet 2001; 357: 1851–3.
15. Cho D, Park S, Kee W et al. The trend of eradication rate of Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterol 2010; 55: 368–75.
16. Connolly L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007; 4: 120.
17. De Francesco V, Zullo A, Margiotta M et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407–14.
18. Duck W, Sobel J, Pruckler J et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 6: 1088–94.
19. Georgopoulos S, Ladas S, Karatapanis S et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig Dis Sci 2000; 45: 63–7.
20. Graham D, Lew G, Malaty HM et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterol 1992; 102: 493–6.
21. Graham D, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321–31.
22. Gisbert J, Hermida C, Pajares J. Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in nonulcer dyspepsia? Hepatogastroenterol 2001; 48: 1383–8.
23. Gumurdulu Y, Serin E, Ozer B et al. Low eradication rate of Helicobacter pylori with triple 7–14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668–71.
24. Katelaris PH. Helicobacter pylori: why are eradication results so variable? J Gastroenterol Hepatol 2004; 19: 606–9.
25. Koivisto T, Rautelin H, Voutilainen M et al. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 2005; 9: 1009–17.
26. Lazebnik LB, Bordin DS, Belousova NL et al. Frequency of site-specific mutations in the 23S rRNA gene of Helicobacter pylori in Moscow. Abstract The XXIVth International Workshop of the European Helicobacter Study Group, Dublin, Ireland – September 11–13, 2011. P. 07.21.
27. Lee J, Shin J, Roe I et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005; 4: 1600–3.
28. Mamori S, Higashida A, Kawara F et al. Age-dependent eradication of Helicobacter pylori in Japanese patients. World J Gastroenterol 2010; 16: 4176–9.
29. McMahon B, Hennessy T, Bensler J et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections 2003; 6: 463–9.
30. Mеgraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280–322.
31. Moder K, Layer F, König W, König B. Rapid screening of clarithromycin resistance in Helicobacter pylori by pyrosequencing. J Med Microbiol 2007; 56: 1370–6.
32. Noguchi N, Rimbara E, Kato A. Detection of mixed clarithromycin-resistant and -susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J Med Microbiol 2007; 9: 1174–80.
33. Silva F, Zaterka S, Eisig J et al. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo 2001; 56: 11–6.
34. Stark R, Gerwig G, Pitman R et al. Letters in applied microbiology. 1999; 2: 121–6.
35. Sugimoto M, Furuta T, Kodaira C et al. The Degree and Duration of Acid Suppression During Treatment Is Related to Helicobacter pylori Eradication. DDW 2008.
36. Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217–24.
37. Yakoob J, Abid S, Abbas Z, Jafri S. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a high-prevalence area. Br J Biomed Sci 2010; 67: 197–201.
Авторы
О.А.Саблин1, Н.В.Михайлов2, М.В.Юрин1, Т.А.Ильчишина1, А.С.Кондрашин1, М.Г.Кобиашвили1, И.А.Михайлова1, А.В.Сварваль3, А.Б.Жебрун3
1 ФГБУ Всероссийский центр экстренной и радиационной медицины им. А.М.Никифорова МЧС России, Санкт-Петербург;
2 ООО «Лаборатория иммунобиологических исследований», Санкт-Петербург;
3 НИИ эпидемиологии и микробиологии им. Пастера, Санкт-Петербург
1 ФГБУ Всероссийский центр экстренной и радиационной медицины им. А.М.Никифорова МЧС России, Санкт-Петербург;
2 ООО «Лаборатория иммунобиологических исследований», Санкт-Петербург;
3 НИИ эпидемиологии и микробиологии им. Пастера, Санкт-Петербург
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.